Skip to main content
 

CLC Comment Letter to CMS and HHS on Step Therapy in Medicare Advantage Plans (September 2018)

CSC Comment Letter to CMS on the South Dakota Career Connector Section 1115 Demonstration Waiver (September 2018)

PQLC Letter to CMS on the Proposed Revisions to the Physician Fee Schedule and Part B for CY 2019 (September 2018)

CLC Letter to CMS on the Proposed Revisions to the Physician Fee Schedule and Part B for CY 2019 (September 2018)

CSC Letter to FDA on Patient-Focused Drug Develpment: Collecting Comprehensive and Representative Input Guidance 1 (September 2018)

CSC Letter to the Health Evidence Review Commission (HERC) on the Coverage Guidance for FDA-Approved Next Generation Sequencing (NGS) Tests (August 2018)

CSC Comment Letter to ICER on the Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer Report (August 2018)

CSC Comment Letter to CMS on the Kentucky HEALTH Section 1115 Demonstration Waiver (August 2018)

CSC Comment Letter to CMS on the Mississippi Workforce Training Initative Section 1115 Demonstration Waiver (August 2018)

Comment Letter to Members of Congress on Cuts to the Clinical Laboratory Fee Schedule (CLFS) through the Protecting Access to Medicare Act (PAMA) (August 2018)

PIPC Letter to CMS and CMMI on Patient-Centered Reforms (August 2018)

CSC Comment Letter to HHS on the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (July 2018)

Letters We've Submitted

2017-2018

CSC Comment Letter to CMS on the South Dakota Career Connector Section 1115 Demonstration Waiver (September 2018)

CSC Letter to FDA on Patient-Focused Drug Develpment: Collecting Comprehensive and Representative Input Guidance 1 (September 2018)

CSC Letter to the Health Evidence Review Commission (HERC) on the Coverage Guidance for FDA-Approved Next Generation Sequencing (NGS) Tests (August 2018)

CSC Comment Letter to ICER on the Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer Report (August 2018)

CSC Comment Letter to CMS on the Kentucky HEALTH Section 1115 Demonstration Waiver (August 2018)

CSC Comment Letter to CMS on the Mississippi Workforce Training Initative Section 1115 Demonstration Waiver (August 2018)

CSC Comment Letter to HHS on the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (July 2018)

CSC Comment Letter to CMS on the Medicare Hospital Inpatient Prospective Payment Systems Proposed Changes (June 2018)

CSC Comment Letter to the FDA on the Patient Focused Drug Development (PFDD) Draft Guidance Relating to Patient Experience Data (May 2018)

CSC Comments on the Short-Term Limited Duration (STLD) Insurance Proposed Rule (April 2018)

CSC Comments to the U.S. FDA for the Oncology Center of Excellence Listening Session (April 2018)

CSC Patient Access to Unapproved Therapies Guiding Principles (March 2018)

CSC Comment Letter to the U.S. Department of Labor on the Definition of "Employer" in the Association Health Plans Proposed Rule (March 2018)

CSC Comment Letter to the FDA on Patient-Focused Drug Development: Guidance 1- Collecting Comprehensive and Representative Input (February 2018)

CSC Comment Letter to CMS on Arizona 1115 Demonstration Waiver Request (January 2018)

CSC Comment Letter on the CMS Policy and Technical Changes to the Medicare Program, Contract Year 2019 (January 2018)

CSC Comment Letter on Proposed Decision Memo for Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer (January 2018)

CSC Comment Letter on Benefit-Risk Assessments in Drug Regulatory Decision-Making (November 2017)

CSC Comment Letter on the Centers for Medicare and Medicaid Innovation Request for Information (November 2017)

CSC Comment Letter on the MassHealth Section 1115 Demonstration Amendment Request (October 2017)

CSC Comment Letter to Duke on the Framework for Regulatory Use of Real-World Evidence (October 2017)

Friends of CPI Comment Letter to E&C Committee on 340B Drug Discount Program (September 2017)

CSC Comments on the 340B Drug Discount Program within the CMS Proposed HOPPS and ASC Payment System Changes for 2018 (September 2017)

CSC Comments on ICER Background and Scope Document on Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value (August 2017)

CSC Comments on the Proposed Office of Patient Affairs (June 2017)

CSC Comment Letter on ISPOR Value Assessment Frameworks (May 2017)

CSC Response to President Trump's FY18 Budget Proposal (May 2017)

CSC Letter to Senate Leadership on AHCA (May 2017)

CSC Comment Letter on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products (April 2017)

CSC Comment Letter to ICER on the Patient Engagement Guide (April 2017)

CSC Position Letter on Step Therapy (March 2017)

CSC's Comment Letter to ICER on the Value Assessment Framework Update (March 2017)

CSC’s Comment Letter to ICER on the Background and Scope Document on Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer (Long Version - March 2017)

CSC’s Comment Letter to ICER on the Background and Scope Document on Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer (Short Version - March 2017)

Friends of CPI Letter to CDER on Psychosocial Distress Screening in the Cancer Care Continuum (March 2017)

2015-2016

CSC Comment Letter to ICER on Lung Cancer Evidence Report Framework (September 2016)

CSC Comment Letter to ICER on Value Assessment Framework (September 2016)

CSC Comment Letter on PDUFA VI Goals Letter (August 2016)

CSC Comment Letter on MACRA Proposed Rule (June 2016)

CSC Comment Letter on Medicare Part B Proposed Rule (May 2016)

CSC Comment Letter to ICER on Assessment of Treatment Options for Multiple Myeloma (April 2016)

CSC Comments on Payment and Benefit Parameters (December 2015)

CSC Comment Letter to CDER on Psychosocial Distress Screening in Clinical Trials  (December 2015)

Friends of CPI Letter to HHS on Incorporating Psychosocial Oncology Care at the NIH and FDA (December 2015)

CSC Comment Letter to NCCN Evidence Blocks (December 2015)

CSC Comments to CMS and HHS Regarding MACRA (November 2015)

CSC Comments on Revisions to the Physician Fee Schedule (September 2015)

CSC Comments on Prescription Drug Fee User Act (PDUFA) (August 2015)

CSC Letter to National Government Services Medical Policy Unit (August 2015)

CSC's Response to ASCO Value Framework (August 2015)

CSC Comment Letter to Iowa DURC on Prior Authorization Restrictions(July 2015)

CSC Comments on the 21st Century Cures Act (July 2015)

CSC Comments on Ways to Improve Outcomes for Medicare Patients with Chronic Conditions (June 2015)

CSC Letter of Support for USPSTF Early Screening for Depression

CSC Comments on the Innovation for Healthier Americans Report (February 2015)

CSC Comments Regarding Cancer Care Payment Reform Act of 2015 (January 2015)

CSC Comments on Proposal Regarding Transparency for Incentive Payments (January 2015)

2012-2014

Letters We've Supported

2017-2018

CLC Comment Letter to CMS and HHS on Step Therapy in Medicare Advantage Plans (September 2018)

PQLC Letter to CMS on the Proposed Revisions to the Physician Fee Schedule and Part B for CY 2019 (September 2018)

CLC Letter to CMS on the Proposed Revisions to the Physician Fee Schedule and Part B for CY 2019 (September 2018)

Comment Letter to Members of Congress on Cuts to the Clinical Laboratory Fee Schedule (CLFS) through the Protecting Access to Medicare Act (PAMA) (August 2018)

PIPC Letter to CMS and CMMI on Patient-Centered Reforms (August 2018)

PQLC Letter to Congress on the Proposed Policies on Opioid Restrictions (June 2018)

PQLC Letter to CMS on the Proposed Policies on Opioid Restrictions (June 2018)

Comment Letter to CMS on the Proposed Changes to the Methods for Assuring Access to Covered Medicaid Services Rule (May 2018)

Letter to the Congressional Tri-Caucus in Support of the Health Equity & Accountability Act of 2018 (May 2018)

PIPC Comment Letter to the MedPAC on Patient-Centered Approaches to Cost Effectiveness in Medicare Policy (May 2018)

CLC Comment Letter on the Short-Term Limited Duration (STLD) Insurance Proposed Rule (April 2018)

Partnership for Part D Access Letter to Secretary of Health and Human Services on the Protected Classes in the Medicare Program (April 2018)

PQLC Comment Letter to the Senate HELP Committee on the Opioid Crisis Response Act of 2018 (April 2018)

Comment Letter to the North Carolina Division of Medical Assistance (DMA) on the NC Medicaid and NC Health Choice Program Coverage of Genetic Testing (March 2018)

CLC Comment Letter to the U.S. Department of Labor on the Association Health Plans Proposed Rule (March 2018)

I am essential Comment Letter on the Association Health Plans Proposed Rule (March 2018)

Letter to Ensure MIPS Score Adjustment is Not Applied to Part B Drug Payments (Senate) (January 2018)

Letter to Ensure MIPS Score Adjustment is Not Applied to Part B Drug Payments (House) (January 2018)

PQLC Comment Letter to U.S. Food and Drug Administration on the Opioid Policy Steering Committee (December 2017)

CLC Letter to Congress on Conference Committee Reconciliation of the Tax Reform Legislation (December 2017)

Letter to Congress Supporting the Inclusion of the Medical Expense Deduction in the "Tax Cuts and Jobs Act of 2017" (December 2017)

CLC Comment Letter to Centers for Medicare and Medicaid Services on the Notice of Benefit and Payment Parameters for 2019 Proposed Rule (November 2017)

CLC Letter to Centers for Medicare and Medicaid Services on the Request for Information (November 2017)

CLC Letter to Congress on the Tax Reform Legislation (November 2017)

REAP and CIC Comment Letter on the Centers for Medicare and Medicaid Innovation Request for Information (November 2017)

CLC Letter to Congress on Changes to the Affordable Care Act Included in Tax Legislation (November 2017)

Letter to the U.S. Department of Veterans Affairs on collaboration with the Institute for Clinical Effectiveness Review (November 2017)

Letter to Congress in support of the Medical Expense Deduction (November 2017)

CLC Letter to HHS on the Massachusetts Section 1115 Demonstration Amendment Request (October 2017)

CLC Letter to Senate Committee on Finance on Graham-Cassidy-Heller-Johnson Legislation (September 2017)

Letter to Congress Urging Five-Year Extension of Funding for the Children's Health Insurance Program (September 2017)

Letter to Congressional Leaders on Market Stability (September 2017)

Comment Letter to Senate Finance on Medicaid Reform (June 2017)

OPA Comments No. FDA-2017-N-0455, Enhancing Patient Engagement Efforts Across FDA (June 2017)

Medicare Rights Center Letter to Senate Leadership on Medicare & Medicaid (May 2017)

CLC on nomination of Dr. Scott Gottlieb (April 2017)

HLC Letter to Congress on Preventive Health Savings Act (April 2017)

Letter to 115th Senate in Support for the Palliative Care and Hospice Education and Training Act (PCHETA) (March 2017)

Letter to 115th House of Representative in Support for the Palliative Care and Hospice Education and Training Act (PCHETA) (March 2017)

The Cystic Fibrosis Foundation Letter to Congressional Leaders on Medicaid Cuts (March 2017)

CLC on Proposed Rule for Market Stablilzation to HHS (March 2017)

HHS Market Stabilization Rule Comment Letter (Febuary 2017)

Letter to 115th Senate on Keeping Patient Protections in Health Care (Febuary 2017)

Letter to 115th House of Represenatives on Keeping Patient Protections in Health Care (Febuary 2017)

2015-2016

CLC Letter to Congress on the Affordable Care Act (December 2016)

Alliance for Aging Research Letter Supporting Dr. Francis Collins as NIH Director (December 2016)

REAP Letter on MACRA Proposed Rule (June 2016)

CLC Letter on MACRA Proposed Rule (June 2016)

CLC Letter on the Oncology Center of Excellence (June 2016)

FOCR Letter on the FDA Oncology Center of Excellence (June 2016)

Defense Health Research Consortium Letter on Medical Research at the Department of Defense (June 2016)

FOCR Letter on Laboratory Developed Tests (April 2016)

MedPAC Draft Recommendation on Protected Classes in Medicare Part D (March 2016)

FOCR Letter Supporting Dr. Robert Califf as Commissioner of the FDA (February 2016)

CLC Letter Payment and Benefit Parameters Comment Letter (December 2015)

Funding for the NIH and FDA in the HELP Committee’s Innovation Bill (October 2015)

Letter supporting President Obama’s nomination of Dr. Robert Califf as Commissioner of the FDA (October 2015)

Alliance for Quality Psychosocial Cancer Care Letter to HHS on Psychosocial Oncology Care (September 2015)

Cancer Leadership Council Comments on Revisions to the Physician Fee Schedule (September 2015)

PQLC Comments on Senate Finance Committee Chronic Care Working Group (June 2015)

OVAC Letter to Appropriators on Proposed CDC Budget Cuts (March 2015)

Cancer Leadership Council comments on 21st Century Cures (March 2015)

Comments on Advance Notice of Methodological Changes for CY 2016 for MA Capitation Rates Part C and Part D Payment Policies (March 2015)

One Voice Against Cancer - Letter to Senator Durbin (March 2015)

Comments on the proposed changes to the Medicare Accountable Care Organizations (February 2015)

Cancer Leadership Council Comments on Network Adequacy Model Act (January 2015)

2012-2014

CLC Comments on Patient Participation in Medical Product Discussions (December 2014)

Cancer Leadership Council on Proposed Rule on Benefit and Payment Parameters 2016 (December 2014)

NAIC Network Adequacy (November 2014)

Children’s Hospital Association Consensus Statement on Network Adequacy (October 2014)

CLC on CMMI Oncology Care Model (October 2014)

Cancer Leadership Council Comments on FY2015 Physician Fee Schedule Proposed Rule (September 2014)

National Health Council Comments on Open Payments Program (September 2014)

PQLC on Revisions to Payment Policies Under the Physician Fee Schedule for CY 2015 (September 2014)

PQLC on Medicare Care Choices Model (August 2014)

I Am (Still) Essential Letter on Marketplace Qualified Health Plans (July 2014)

Rescheduling of Hydrocodone Combination Products (April 2014)

Community Letter National Cancer Research Month (May 2014)

CLC on Medical Oncology Payment Reform (April 2014)

CLC on SGR Repeal and Physician Payment Reform (March 2014)

Partnership for Part D Access on proposed Medicare Part D Changes (March 2014)

SPEAC on 2015 Marketplace Adequacy (February 2014)

REAP on Medicare Part D Proposed Rule Changes (March 2014)

CLC on proposed Medicare Part D changes to 6 Protected Classes (March 2014)

CLC on 2015 Marketplace Network Adequacy (February 2014)

NDD United on Sequestration and FY 2014 Budget (December 2013)

One Voice Against Cancer NIH Cancer Research and Prevention Budget (December 2013)

One Voice Against Cancer on Federal Budget Negotiations (November 2013)

CLC Comments on SGR Physician Payment Reform Package (November 2013)

One Voice Against Cancer on Federal Government Shutdown (October 2013)

Cancer Leadership Council comments on 2014 Physician Fee Schedule (September 2013)

CLC Comments on SGR Physician Payment Reform Package (November 2013)

National Health Council on Access to OOP Cost Calculator to Compare Marketplace Plans (October 2013)

Cancer Leadership Council on Federal Government Shutdown (October 2013)

CLC Statement on Reimbursement for Quality Cancer Care (October 2013

Orphan Drug Tax Credit Letter (July 2013)

REAP Navigator Standards for Exchange (May 2013)

Cancer Leadership Council on Pharma Distribution Supply Chain (May 2013)

National Health Council on Medicare Out of Pocket Maximums (April 2013)

Breakthrough Designation Support Letter (April 2012)

Cancer Leadership Council on PCORI Research Agenda (March 2012)

CSC Position Statements

Letters to the Center for Medicare and Medicaid Services (CMS) or the Center for Medicare and Medicaid Innovation (CMMI)

CLC Comment Letter to CMS and HHS on Step Therapy in Medicare Advantage Plans (September 2018)

CSC Comment Letter to CMS on the South Dakota Career Connector Section 1115 Demonstration Waiver (September 2018)

PQLC Letter to CMS on the Proposed Revisions to the Physician Fee Schedule and Part B for CY 2019 (September 2018)

CLC Letter to CMS on the Proposed Revisions to the Physician Fee Schedule and Part B for CY 2019 (September 2018)

PIPC Letter to CMS and CMMI on Patient-Centered Reforms (August 2018)

CSC Comment Letter to CMS on the Kentucky HEALTH Section 1115 Demonstration Waiver (August 2018)

CSC Comment Letter to CMS on the Mississippi Workforce Training Initative Section 1115 Demonstration Waiver (August 2018)

CSC Comment Letter to CMS on the Medicare Hospital Inpatient Prospective Payment Systems Proposed Changes (June 2018)

PQLC Letter to CMS on the Proposed Policies on Opioid Restrictions (June 2018)

Comment Letter to CMS on the Proposed Changes to the Methods for Assuring Access to Covered Medicaid Services Rule (May 2018)

CSC Comment Letter to CMS on Arizona 1115 Demonstration Waiver Request (January 2018)

CSC Comment Letter on the CMS Policy and Technical Changes to the Medicare Program, Contract Year 2019 (January 2018)

CSC Comment Letter on Proposed Decision Memo for Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer (January 2018)

CSC Comment Letter on the Centers for Medicare and Medicaid Innovation Request for Information (November 2017)

CLC Comment Letter to Centers for Medicare and Medicaid Services on the Notice of Benefit and Payment Parameters for 2019 Proposed Rule (November 2017)

REAP and CIC Comment Letter on the Centers for Medicare and Medicaid Innovation Request for Information (November 2017)

CLC Letter to Centers for Medicare and Medicaid Services on the Request for Information (November 2017)

CSC Comments on the 340B Drug Discount Program within the CMS Proposed HOPPS and ASC Payment System Changes for 2018 (September 2017)

CSC Comment Letter on MACRA Proposed Rule (June 2016)

REAP Letter on MACRA Proposed Rule (June 2016)

CLC Letter on MACRA Proposed Rule (June 2016)

CSC Comment Letter on Medicare Part B Proposed Rule (May 2016)

Cancer Leadership Council Comments on Revisions to the Physician Fee Schedule (September 2015)

Comments on Advance Notice of Methodological Changes for CY 2016 for MA Capitation Rates Part C and Part D Payment Policies (March 2015)

Comments on the proposed changes to the Medicare Accountable Care Organizations (February 2015)

CSC Comments on Payment and Benefit Parameters (December 2015)

CLC Letter Payment and Benefit Parameters Comment Letter (December 2015)

CSC Comments to CMS and HHS Regarding MACRA (November 2015)

CSC Comments on Revisions to the Physician Fee Schedule (September 2015)

CSC Comments on Ways to Improve Outcomes for Medicare Patients with Chronic Conditions (June 2015)

CLC on Medical Oncology Payment Reform (April 2014)

CSC Concerns with Proposed Rule Changes to Medicare Part D’s 6 Protected Classes (March 2014)

Partnership for Part D Access on proposed Medicare Part D Changes (March 2014)

CLC on proposed Medicare Part D changes to 6 Protected Classes (March 2014)

REAP on Medicare Part D Proposed Rule Changes (March 2014)

SPEAC on 2015 Marketplace Adequacy (February 2014)

CLC on 2015 Marketplace Network Adequacy (February 2014)

CLC on CMMI Oncology Care Model (October 2014)

Cancer Leadership Council Comments on FY2015 Physician Fee Schedule Proposed Rule (September 2014)

National Health Council Comments on Open Payments Program (September 2014)

PQLC on Revisions to Payment Policies Under the Physician Fee Schedule for CY 2015 (September 2014)

PQLC on Medicare Care Choices Model (August 2014)

Cancer Leadership Council comments on 2014 Physician Fee Schedule (September 2013)

CLC Comments on SGR Physician Payment Reform Package (November 2013)

REAP Navigator Standards for Exchange (May 2013)

Letters to the U.S. Food and Drug Administration (FDA)

CSC Letter to FDA on Patient-Focused Drug Develpment: Collecting Comprehensive and Representative Input Guidance 1 (September 2018)

CSC Comment Letter to the FDA on the Patient Focused Drug Development (PFDD) Draft Guidance Relating to Patient Experience Data (May 2018)

CSC Comments to the U.S. FDA for the Oncology Center of Excellence Listening Session (April 2018)

CSC Comment Letter to the FDA on Patient-Focused Drug Development: Guidance 1- Collecting Comprehensive and Representative Input (February 2018)

PQLC Comment Letter to U.S. Food and Drug Administration on the Opioid Policy Steering Committee (December 2017)

CSC Comment Letter on Benefit-Risk Assessments in Drug Regulatory Decision-Making (November 2017)

CSC Comments on the Proposed Office of Patient Affairs (June 2017)

OPA Comments No. FDA-2017-N-0455, Enhancing Patient Engagement Efforts Across FDA (June 2017)

CSC Comment Letter on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products (April 2017)

CSC Comment Letter on PDUFA VI Goals Letter (August 2016)

CLC Letter on the Oncology Center of Excellence (June 2016)

FOCR Letter on the FDA Oncology Center of Excellence (June 2016)

CSC Comments on Prescription Drug Fee User Act (PDUFA) (August 2015)

CSC Comments on the Innovation for Healthier Americans Report (February 2015)

CSC Comments on FDA Activities for Patient Participation in Medical Product Discussions (December 2014)

CLC Comments on Patient Participation in Medical Product Discussions (December 2014)

Letters to the U.S. House of Representatives and U.S. Senate

Comment Letter to Members of Congress on Cuts to the Clinical Laboratory Fee Schedule (CLFS) through the Protecting Access to Medicare Act (PAMA) (August 2018)

PQLC Letter to Congress on the Proposed Policies on Opioid Restrictions (June 2018)

Letter to the Congressional Tri-Caucus in Support of the Health Equity & Accountability Act of 2018 (May 2018)

PQLC Comment Letter to the Senate HELP Committee on the Opioid Crisis Response Act of 2018 (April 2018)

Letter to Ensure MIPS Score Adjustment is Not Applied to Part B Drug Payments (Senate) (January 2018)

Letter to Ensure MIPS Score Adjustment is Not Applied to Part B Drug Payments (House) (January 2018)

CLC Letter to Congress on Conference Committee Reconciliation of the Tax Reform Legislation (December 2017)

Letter to Congress Supporting the Inclusion of the Medical Expense Deduction in the "Tax Cuts and Jobs Act of 2017" (December 2017)

CLC Letter to Congress on the Tax Reform Legislation (November 2017)

Letter to Congress in support of the Medical Expense Deduction (November 2017)

CLC Letter to Congress on Changes to the Affordable Care Act Included in Tax Legislation (November 2017)

Friends of CPI Comment Letter to E&C Committee on 340B Drug Discount Program (September 2017)

Letter to Congress Urging Five-Year Extension of Funding for the Children's Health Insurance Program (September 2017)

Letter to Congressional Leaders on Market Stability (September 2017)

CLC Letter to Senate Committee on Finance on Graham-Cassidy-Heller-Johnson Legislation (September 2017)

Comment Letter to Senate Finance on Medicaid Reform (June 2017)

CSC Response to President Trump's FY18 Budget Proposal (May 2017)

Medicare Rights Center Letter to Senate Leadership on Medicare & Medicaid (May 2017)

CSC Letter to Senate Leadership on AHCA (May 2017)

CLC on nomination of Dr. Scott Gottlieb (April 2017)

HLC Letter to Congress on Preventive Health Savings Act (April 2017)

Letter to 115th Senate in Support for the Palliative Care and Hospice Education and Training Act (PCHETA) (March 2017)

Letter to 115th House of Representative in Support for the Palliative Care and Hospice Education and Training Act (PCHETA) (March 2017)

The Cystic Fibrosis Foundation Letter to Congressional Leaders on Medicaid Cuts (March 2017)

Letter to 115th Senate on Keeping Patient Protections in Health Care (Febuary 2017)

Letter to 115th House of Represenatives on Keeping Patient Protections in Health Care (Febuary 2017)

CLC Letter to Congress on the Affordable Care Act (December 2016)

Defense Health Research Consortium Letter on Medical Research at the Department of Defense (June 2016)

FOCR Letter on Laboratory Developed Tests (April 2016)

FOCR Letter Supporting Dr. Robert Califf as Commissioner of the FDA (February 2016)

Funding for the NIH and FDA in the HELP Committee’s Innovation Bill (October 2015)

Letter supporting President Obama’s nomination of Dr. Robert Califf as Commissioner of the FDA (October 2015)

CSC Comments on the 21st Century Cures Act (July 2015)

PQLC Comments on Senate Finance Committee Chronic Care Working Group (June 2015)

OVAC Letter to Appropriators on Proposed CDC Budget Cuts (March 2015)

Cancer Leadership Council comments on 21st Century Cures (March 2015)

One Voice Against Cancer - Letter to Senator Durbin (March 2015)

CSC Comments Regarding Cancer Care Payment Reform Act of 2015 (January 2015)

CSC Comments on Proposal Regarding Transparency for Incentive Payments (January 2015)

Community Letter National Cancer Research Month (May 2014)

CLC on SGR Repeal and Physician Payment Reform (March 2014)

NDD United on Sequestration and FY 2014 Budget (December 2013)

One Voice Against Cancer NIH Cancer Research and Prevention Budget (December 2013)

One Voice Against Cancer on Federal Budget Negotiations (November 2013)

CLC Comments on SGR Physician Payment Reform Package (November 2013)

One Voice Against Cancer on Federal Government Shutdown (October 2013)

Cancer Leadership Council on Federal Government Shutdown (October 2013)

CLC Statement on Reimbursement for Quality Cancer Care (October 2013

CSC Letter to House in Support of FDA Safety Over Sequestration Act (September 2013)

CSC Letter to Senate in Support of FDA Safety Over Sequestration Act (September 2013)

Orphan Drug Tax Credit Letter (July 2013)

Cancer Leadership Council on Pharma Distribution Supply Chain (May 2013)

CSC Comments on Addressing the Drug Shortage in PDUFA (April 2012)

Breakthrough Designation Support Letter (April 2012)

Letters to the U.S. Department of Health and Human Services

Letters to the U.S. Department of Veteran's Affairs

Letters to the Institute for Clinical and Economic Review (ICER)

Letters to the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)

Letters to the Center Drug Evaluation and Research (CDER) at the U.S. FDA

Letters to the National Comprehensive Cancer Network (NCCN)

Letters to the American Society of Clinical Oncology (ASCO)

Letters to the U.S. Department of Labor

Letters to the Patient-Centered Outcomes Research Institute (PCORI)

Letters to the Medicare Payment Advisory Commission (MedPAC)

Miscellaneous Letters